Indian authorities, over a one-year-period, have cancelled licences of 64 pharma companies, while 17 drug testing laboratories have been asked to shut down for non-compliance with ‘good manufacturing practices’ and other “continued” procedural lapses.
As per the World Health Organisation (WHO), ‘good manufacturing practices’ refer to that aspect of quality assurance that ensures medicinal products are consistently produced and controlled as per the quality standards appropriate to their intended use and as required by the product specification. Apart from production and quality control matters, there is also a legal component that cover responsibilities for distribution, contract manufacturing and testing, and responses to product defects and complaints.
Sources told , checks and investigation were carried out during the last 12 months, where 423 companies including listed entities and drug testing laboratories came under the scanner. The investigation took place in five phases across various manufacturing facilities here.
Read also: Article 370 was biggest obstacle in J&K’s development: PM Modi
